We describe a 26-year-old male hemodialysis patient with erythropoietin (EPO) resistant anemia associated with primary hyperthyroidism. Use of the anti-hyperthyroid drug, methimazole, led to improvement of his hyperthyroidism and anemia. Before the anti-hyperthyroid therapy, he had received transfusions to maintain an adequate hematocrit during recombinant human EPOtherapy. After the therapy, his hyperthyroidism improved and his hematocrit gradually increased without any transfusion. These findings suggest that the patient's EPO resistant anemia was the result of primary hyperthyroidism, and that this complication is reversible if accurate treatment is given. (Internal Medicine 36: 903-905, 1997) 
Introduction
Chronic renal failure is generally accompanied by anemia due to an insufficient synthesis of erythropoietin (EPO) by the kidney (1 , 2) . In Japan in 1990, recombinant human erythropoietin (rHuEPO) was introduced for the treatment of anemia in hemodialysis patients. As a result, most hemodialysis patients nowrecover from this anemia (3, 4) . However, a small number of patients remain unresponsive. The common causes of resistance are generally considered to be iron deficiency, inflammatory states, neoplastic diseases, aluminum intoxication and secondary hyperparathyroidism (5) (6) (7) (8) .
Wereport a case with primary hyperthyroidism presenting with rHuEPOresistant anemia in whomanti-hyperthyroid therapy was successful for both the hyperthyroidism and the rHuEPOresistant anemia.
Case Report
A 26-year-old man was admitted to Fueki Internal Medicine Clinic in October 1994 due to anemia and low grade fever. Chronic regular hemodialysis had been initiated seven years earlier (June 1987). He had received intravenous rHuEPO therapy since 1990. Within a few years of the initiation ofhemodialysis, transfusions were required by the patient several times a year due to renal anemia. After rHuEPObecame commercially available for renal anemia, it proved effective for his anemia and transfusions were discontinued for a while. However, a few months prior to admission, his hematocrit began to decrease, even though he was receiving 3,000 units of rHuEPOthree times/ week during each hemodialysis. In addition, he had experienced general fatigue, headache and low grade fever from one monthbefore admission. On examination, his blood pressure was 140/80 mmHg, pulse rate 120/min, and temperature 37.0°C. He was anemic, but not icteric. A bilateral diffuse and soft thyroid mass was palpable in his neck, but bruit was not audible. The heart and lungs were normal, and the lymph nodes were not palpable in his neck or in the axillary or inguinal regions. No hepatosplenomegaly or ascites was noted. There was no peripheral edema and no neurological abnormalities were noted.
Laboratory studies ( anti-TSH receptor antibody gradually decreased, and his thyroid stimulating hormone (TSH) level and his hematocrit gradually increased ( Fig. 1 and Table 2 ). No transfusions have been required since anti-hyperthyroid therapy was begun. The patient has been able to maintain a hematocrit level of about 30% and has been able to sustain the anti-hyperthyroid drug (methimazole; 5 mg/day). At present (two years after the initiation of this therapy), while still undergoing regular hemodialysis and rHuEPO therapy, the patient enjoys an active life without general fatigue, headache or low grade fever. (9): 1) The duration of EPOadministration is longer than three months. 2) The serum ferritin level is higher than 200 |Wg/ml, or 100 |ig/ml after iron infusion treatment more than 10 times.
3) The weekly EPOdosage is more than 9,000 units administered as equal i.v. injections after thrice weekly hemodialysis. The condition of our patient satisfies these criteria. The main causes of EPOresistant renal anemia are well known to be iron deficiency, inflammatory states, neoplastic diseases, aluminum intoxication and secondary hyperparathyroidism (5) (6) (7) (8) . No iron deficiency was revealed by laboratory , data, and no inflammatory states including infection or neoplastic diseases were disclosed by chest X-ray, abdominal echography, or other examinations. It has been reported that PTH-C is elevated in patients with chronic renal failure (10) , and an elevated PTH-C level does not always suggest the hyperparathyroid state. In the present patient, this level did not change before and after anti-hyperthyroid therapy. Measurementof serumaluminumwasnot done, but it is clear that antihyperthyroid therapy is not effective for aluminum intoxication. EPOresistant anemia, however, has never been reported in a hemodialyzed patient as a result of primary hyperthyroidism. Generally, hyperthyroidism is not considered to be a cause of anemia. It has previously been reported that serum EPOlevels are increased in hyperthyroid patients, and that T4 and T3 stimulate EPO synthesis (1 1). Induction of anemia in non-hemodialysis patients due to a hyperthyroid state has been reported, although rarely, but in those cases, it was caused by hemolytic anemia and aplastic anemia (5, 12, 13) . As far as we know, there have been no reports of primary hyperthyroidisminduced hemolytic anemia or aplastic anemia in hemodialysis patients. In the present patient, it is not believed that his anemia might have been caused by aplastic or hemolytic anemias, because the number of white blood cells and platelets was normal. Furthermore, his reticulocyte count, serum bilirubin and haptoglobin levels were also normal. In addition, splenomegaly was not present. Wecould not carry out bone marrow aspiration or a biopsy, because we did not have the patient's consent for these examinations. In addition, it is undeniable that the low nutrition state by primary hyperthyroidism was a cause of his anemia, because his serum protein has recovered to within normal range (7.7 g/dl) two years after initial treatment.
Wealso considered autoimmune diseases, including Hashimoto's disease, as a cause of the EPOresistant anemia because his thyroid test and microsome test findings were high on admission, but these test findings did not change despite improvement in his anemia and hyperthyroidism with antihyperthyroid therapy. Therefore, autoimmune diseases were negated as a cause of the EPOresistant anemia.
In conclusion, we reported here the case of a hemodialysis patient with primary hyperthyroidism and EPOresistant anemia who recovered well after anti-hyperthyroid therapy.
